MAP2K1 and melanoma: BRAF inhibitors (BRAFi), such as dabrafenib and vemurafenib, have shown excellent response rates and, in addition, MEK1/2 inhibitors, such as trametinib, binimetinib, and cobimetinib, have been approved in melanoma and non-small cell lung cancer with mutated BRAF [57,58].